KPTI News and Press, Karyopharm Therapeutics Inc. From 11/04/22

RBC Capital Markets has upgraded Karyopharm Therapeutics ( NASDAQ: KPTI ) to outperform from market perform saying the company's opportunities are discounted in the stock price. The firm also upped its price target to $10 from $7 (~120% upside based on Thursday's close). ...

Karyopharm Therapeutics ( NASDAQ: KPTI ) stock rose ~9% premarket Friday after Q3 results beat estimates and the company maintained its FY22 outlook. Net loss narrowed to -$36.32M, compared to -$51.81M in Q3 2021. Total revenue declined -4% Y/Y to $36.14M. ...

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q3 2022 Earnings Call Nov 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript

Karyopharm Therapeutics Inc. (KPTI) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Elhan Webb - Senior Vice President-Investor Relations Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Chief Commercia...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Karyopharm Therapeutics Inc. 2022 Q3 - Results - Earnings Call Presentation

Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q3 GAAP EPS of -$0.45 beats by $0.10 . Revenue of $36.1M (-4.2% Y/Y) beats by $1.27M . Cash, cash equivalents, restricted cash and investments as of September 30, 2022, totaled $150.1 million, compared to ...

Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Third Quarter 2022 Total Revenue of $36.1 Million , Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million , a 20 %...

Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022 PR Newswire – Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activ...

The European Commission has granted Karyopharm Therapeutics' ( NASDAQ: KPTI ) Xpovio (selinexor) orphan drug status for myelofibrosis ( MF ). The company is examining Xpovio (selinexor), a first-in-class XP01 inhibitor, as monotherapy in patients with previously tr...

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis PR Newswire NEWTON, Mass. and FLORENCE, Italy , Oct. 31, 2022 /PRNewswire/ -- Karyopharm T...